Evoke Pharma (NASDAQ:EVOK) Earns Sell Rating from Analysts at StockNews.com

Analysts at StockNews.com initiated coverage on shares of Evoke Pharma (NASDAQ:EVOK) in a research report issued on Monday. The brokerage set a “sell” rating on the specialty pharmaceutical company’s stock.

Evoke Pharma Stock Performance

Evoke Pharma stock opened at $4.86 on Monday. The firm has a market cap of $7.22 million, a price-to-earnings ratio of -0.44 and a beta of 0.16. Evoke Pharma has a 1 year low of $3.54 and a 1 year high of $13.80. The firm’s 50 day moving average price is $4.92 and its two-hundred day moving average price is $5.23.

Institutional Trading of Evoke Pharma

An institutional investor recently bought a new position in Evoke Pharma stock. Corsair Capital Management L.P. bought a new stake in Evoke Pharma, Inc. (NASDAQ:EVOK) in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 11,667 shares of the specialty pharmaceutical company’s stock, valued at approximately $56,000. Corsair Capital Management L.P. owned approximately 1.42% of Evoke Pharma as of its most recent SEC filing.

About Evoke Pharma

Evoke Pharma, Inc, a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults.